Immunosuppression under Trial

Proceedings of the 31st Conference on Transplantation and Clinical Immunology, 3–4 June, 1999

  • Editors
  • P. Cochat
  • J. Traeger
  • C. Merieux
  • M. Derchavane

Part of the Transplantation and Clinical Immunology book series (TRAC, volume 31)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Setting the stages in clinical trials

  3. Is acute rejection an appropriate surrogate marker?

  4. Towards long-term end-points

    1. Front Matter
      Pages 61-61
  5. Can we minimize the long-term side effects?

  6. Strategies

    1. Front Matter
      Pages 123-123
    2. D. Abramowicz, K. M. Wissing
      Pages 125-129
    3. J. Dantal, M. Hourmant, D. Cantarovich, M. Giral, G. Blancho, B. Dreno et al.
      Pages 131-144
    4. J. M. Dubernard, E. R. Owen, N. Lefrançois, P. Petruzzo, X. Martin, M. Dawahra et al.
      Pages 145-151
    5. C. van Buren
      Pages 153-155
  7. Clinical trials for at-risk situations

    1. Front Matter
      Pages 167-167
  8. Back Matter
    Pages 179-179

About this book


Immunosuppression in solid organ transplantation is currently experiencing a worldwide revival since new drugs are now available and others are under development. In order to contribute to the design of future strategies, a critical approach of surrogate endpoints is given and long-term side effects are analysed, together with the impact of non-compliance, quality-of-life and economical parameters. In this book, international specialists have set up the scientific rationale and provided new bases for further immunosuppressive strategies.


cancer clinical trial immunosuppression kidney transplantation

Bibliographic information